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BACKGROUND Early experiences on PCI of small vessels (SV) with
bioresorbable vascular scaffolds (BVS) have shown an increased risk of
adverse clinical events. We aimed to assess the clinical outcomes of
Absorb BVS implantation in the SV subset of the RAI multicenter
registry.
METHODS The Italian RAI Registry is an ongoing, spontaneous,
multicentre prospective data collection which evaluates all patients
treated at participating centres with the second-generation ever-
olimus-eluting Absorb BVS. Our analysis was restricted to patients
who received Absorb BVS implantation in at least one small vessel,
deﬁned as pre-procedure reference vessel diameter (RVD) 2.5 mm at
quantitative coronary analysis (QCA).
RESULTS Between March 2012 and June 2015, 1089 consecutive un-
selected patients were treated with one or more Absorb BVS in the RAI
Registry. 123 patients (mean age 62 years, 77% males) were included in
this analysis. A total of 149 lesions located on SVs were treated with
Absorb BVS in this cohort. Seventy-six (62%) of these patients had an
acute coronary syndrome. Diabetic patients were 30 (24%). Multi-
vessel coronary artery disease was present in 67% of patients, and the
median SYNTAX score was 17  15. The majority (76%) of this patients
received SV scaffolding alone, while the remaining 24% were treated
also in larger segments (>2.5mm). Twenty-eight (23%) patients
received also metallic stents on the same or different target vessel.
The total number of Absorb BVS implanted in this population was 249,
with an average of 1.9 per patient. Procedural success occurred in 96%
of patients. At a median follow up of 21 months (interquartile range, 11
– 32 months) target lesion failure rate was 5.7%. More in detail,
adverse events were: 1 cardiac death, 5 target vessel myocardial in-
farctions, 4 target lesion revascularizations due to three deﬁnite
scaffold thrombosis (1 sub-acute, 1 late, 1 very-late).
CONCLUSIONS In the RAI registry, adverse event rates after treat-
ment of small vessels with Absorb BVS were relatively low and com-
parable to previous results in less complex subsets of patients
undergoing PCI with the Absorb BVS.
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BACKGROUND The safety and performance of the Absorb Bio-
resorbable Vascular Scaffold (Absorb) (Abbott Vascular, Santa Clara,
CA) has been previously demonstrated with clinical data up to 5 years.
However, these trials treated patients with relatively simple lesions.
ABSORB FIRST is designed to evaluate Absorb BVS in the treatment of
patients with more complex lesions in a real-world setting.
METHODS ABSORB FIRST is a prospective, multi-center, global reg-
istry to evaluate the safety and effectiveness of Absorb during com-
mercial use in an all-comer population. This study enrolled 1,801
patients between 01/2013 and 08/2014 at 87 sites worldwide. Treat-
ment strategy was determined by physicians per the IFU and limited
to lesions in vessels without prior intervention. The key clinical
endpoints include scaffold thrombosis (ST), cardiac death, myocardialinfarction (MI), revascularization, target lesion failure (TLF), major
adverse cardiac events (MACE) and target vessel failure (TVF). All
reported adverse events are 100% monitored and clinical events are
independently adjudicated.
RESULTS Baseline characteristics of this population reﬂect the typical
PCI, all-comer population: dyslipidemia (64.7%), hypertension
(63.7%), diabetics (24.0%), family history of premature CAD (38.5%),
AMI (26.3%), multi-vessel disease (44.3%), and prior cardiac in-
terventions (24.1%). There is also a high proportion of patients with
Class B2/C lesions (47.2 %), moderate/severe calciﬁed lesions (18.8%),
bifurcations (12.9%), total occluded lesions (10.3%), ostial lesions
(5.7%). The mean lesion length is 18.5  9.3 mm. The device success
and procedure success rates are 97.3 % and 95.5 %, respectively,
comparable to those observed in prior simple trials. The rate of deﬁ-
nite/probable ST rate at 1- year based on interim data on w 950 pa-
tients is 0.8%. The 1-year clinical outcomes from the entire population
will be reported and subgroup analyses by patient and lesion com-
plexities might also be presented.
CONCLUSIONS The 1-year results from this large, global registry
demonstrate the safety and effectiveness of Absorb in real-world pa-
tients, indicating its applicability in daily PCI use.
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BACKGROUND Noninvasive assessment of coronary stenosis by
multislice computed tomography (MSCT) has been clinically appli-
cable. However, the diagnostic accuracy in stented segments has been
hampered by blooming artifacts caused by metallic stent struts.
Everolimus-eluting bioresorbable vascular scaffold (BVS) is composed
of radiolucent poly-lactide backbone which induces no image
blooming artifacts, but, presence of platinum markers on scaffold
edges may cause artifacts. The prospective pre-speciﬁed MSCT sub-
group analysis of ABSORB Japan trial sought to assess the diagnostic
capability of MSCT in BVS by compared to everolimus-eluting metallic
stent (CoCr-EES).
METHODS ABSORB Japan was a single-blind, multicenter, random-
ized, Japanese trial. Eligible patients, with one or two de novo
lesions in different epicardial vessels, were randomized in a 2:1 ratio
to BVS or CoCr-EES treatment. The pre-speciﬁed subgroup of pa-
tients underwent MSCT at 13 months but prior to invasive coronary
angiography. Angiography physician was blinded to MSCT ﬁndings.
Quantitative coronary angiography (QCA) was performed at the
angiographic core laboratory (Beth Israel Deaconess Medical Center,
Boston, USA), while qualitative and quantitative MSCT analysis were
performed at the independent MSCT core laboratory (Cardiocore
Japan, Tokyo, Japan).
RESULTS The substudy enrolled 146 patients (97 patients with 102
lesions in BVS and 49 patients with 49 lesions in EES). There were
no signiﬁcant differences in baseline clinical characteristics between
the 2 groups. MSCT was performed at 13 months in 83 patients
(87 lesions) in BVS and 42 patients (42 lesions) in CoCr-EES,
respectively. No restenosis was observed in either arm. The MSCT
image quality was adequate for assessment in 82 lesions (94%) in
BVS and 28 lesions in EES (67%), respectively (P<0.0001). Of the 5
lesions with poor image quality in BVS, 2 (2.3% of the total lesions)
were due to image artifacts caused by the edge platinum markers
and 4 were related to motion artifact of patients (multiple reasons).
In contrast, of the 14 lesions with poor image quality in CoCr-EES,
13 (31.0% of the total lesions) were due to imaging artifacts caused
by stent struts. Comparison with QCA data will be present at the
time of presentation.
CONCLUSIONS Visualization and assessment of vascular implants by
MSCT is more feasible for BVS compared to CoCr-EES.
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